Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

DEA's PROPOSED 1985 AGGREGATE PRODUCTION QUOTA FOR CODEINE (FOR SALE)

Executive Summary

DEA's PROPOSED 1985 AGGREGATE PRODUCTION QUOTA FOR CODEINE (FOR SALE) is 54.05 mil. grams, according to figures published in the Oct. 11 Federal Register. The codeine aggregate production level proposed by the Drug Enforcement Administration (DEA) is 3.0% above the 52.5 mil. gram level approved by DEA in 1984. The agency proposed a decrease, from 3.58 mil. to 3.53 mil. in the aggregate production quota for codeine (for conversion). In the notice, DEA published its proposals for production quotas for Schedule I and Schedule II controlled substances. The agency recommended quota increases for 14 of 35 agents (for list of proposed 1985 production quotas and 1984 quotas, see box below). (FOOTNOTE) Other substances for which DEA proposed increases, include: morphine (for conversion), a 4.7% increase to 58.08 mil. grams; thebaine, up 14.2% to 6.89 mil. grams; morphine (for sale), up 8.8% to 1.14 mil. grams; methadone, up 31.7% to 1.38 mil. grams; and methadone intermediate, up 31.7% to 1.38 mil. grams. The agency explained that in proposing the quotas, it took account of five factors: (1) actual disposals for 1983 and estimates for 1984 and 1985 for each mfr.; (2) projected trends in net disposals; (3) inventory estimates; (4) projected demand; (5) "estimates of change in legitimate medical needs"; (6) "documented diversion." The deadline for comments on the proposed quotas is Nov. 13. Chart omitted.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS007311

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel